NewsRamp Health & Wellness Podcast

Wrapped in Love and Kelly Ripa collaborate to offer limited-edition teal ribbon socks for ovarian cancer awareness, with proceeds supporting research. Blue Faery organizes a free educational event in Dallas on liver health and disease prevention. Natural Cure Labs enhances its monolaurin products with ISO 17025-accredited lab partnerships and triple-testing protocol. PointClickCare introduces an AI-powered solution for efficient care transitions from SNFs to EDs, improving patient outcomes.

NRx Pharmaceuticals secures FDA Fast Track designation for IV ketamine for suicidal ideation, while Lantern Pharma gains FDA guidance for a pediatric CNS cancer trial. Vincent+ unveils survey results for its Ultra Antioxidant Serum, showing significant benefits for skin rejuvenation. Other companies making strides include Oncotelic Therapeutics with their lead candidate in a Phase 3 pancreatic cancer trial, Izotropic Corporation securing a US patent for CADx in breast CT, and Kairos Pharma presenting Phase 1 data for ENV105 at a cancer conference.

InFlectis BioScience and Kairos Pharma are making strides in developing treatments for rare diseases and cancer, while the American Heart Association is providing grants to schools for promoting healthier environments. Additionally, new research sheds light on the lack of awareness surrounding AFib, emphasizing the importance of early detection and treatment. Governor Wes Moore asserts authority over Maryland's National Guard amidst climate policy criticism. Sigyn Therapeutics announces plans for a clinical feasibility study for cardiovascular disease. Consumers seeking home care can find information on affordability and benefits through various insurance plans.

A new Perspire Sauna Studio location has opened in Birmingham, offering unique wellness experiences. DPR Construction completes topping out of new healthcare facilities in Pembroke Pines and Miramar. Izotropic launches BreastCT.com for breast CT technology education. NRx Pharmaceuticals showcases HOPE Therapeutics program. Soligenix presents at the H.C. Wainwright Global Investment Conference. Scinai Immunotherapeutics reports revenue growth. Strawberry Fields REIT acquires a new facility. Study links head injuries to brain cancer risk. Annovis Bio and Clene Inc. participate in the H.C. Wainwright Global Investment Conference.

Calidi Biotherapeutics is presenting its RedTail platform at an investment conference, showcasing its focus on targeted therapies for distal disease sites. Meanwhile, NFL PLAY 60 and Kids Heart Challenge are collaborating to promote physical activity and mental wellness among students, emphasizing the importance of staying active for improved learning and stress management.

Retirees in Maryland face potential loss of Medicare Advantage plans as major insurance providers consider exiting due to high costs and federal reimbursement challenges. This could leave seniors without key supplemental benefits. Meanwhile, Omarion Calloway debuts 'More Than Survival: A Guideline for Young Caregivers', a guide sharing his experiences and advocating for systemic change to support children shouldering adult responsibilities.

Creative Biolabs is at the forefront of leveraging glycobiology to enhance drug safety and efficacy. By offering tailored glycoprotein engineering services and cutting-edge carbohydrate analysis techniques, they are revolutionizing drug development and biomarker discovery. Their focus on glycoproteins and polysaccharides is bridging the gap between research and production in the biopharmaceutical industry.

Zevra Therapeutics and Clene Inc. are at the forefront of developing innovative therapies for rare diseases and neurodegenerative conditions, respectively. Zevra's MIPLYFFA targets Niemann-Pick disease type C, while Clene's CNM-Au8® focuses on mitochondrial dysfunction in ALS. Additionally, Propanc Biopharma recently closed a successful public offering, and Dr. Susan Littman's web series, Picture of Health, has returned with a renewed focus on healthcare advancements.

ABVC BioPharma received $450,000 in licensing payments from OncoX BioPharma in Q3 2025, showcasing a strong strategic alliance. The agreement includes cash payments, shares, and royalties, covering four major oncology indications with FDA approvals. With the global cancer therapeutics market projected to reach $393 billion by 2032, this partnership strengthens ABVC's position in oncology, positioning them as leaders in developing botanical-derived oncology therapeutics.

Lantern Pharma and Oncotelic Therapeutics are utilizing AI and extensive patent portfolios to advance oncology drug development. HeartBeam Inc. is revolutionizing cardiac care with a portable ECG device, while the PREVENT™ equations are enhancing risk assessment for cardiovascular disease. Additionally, a study on IBD-related blood clots offers hope for improved treatments, and Izotropic Corporation's AI-based algorithm is set to revolutionize breast cancer screening.